Hoth Therapeutics, Inc. · NASDAQ:HOTH
Hoth Therapeutics — Investor Presentation (October 2025)
24 slides from Hoth Therapeutics's investor presentation, October 2025
Slide 1: Innovating for Everyone
October 2025 Innovating for Everyone Clinical - stage biopharmaceutical company focused on next generation therapeutics meeting unmet patient needs.
Slide 2: Safe Harbor Statement
This presentation contains "forward - looking statements" within the meaning of the “safe - harbor” : HOTH provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,”
Slide 3: Our Mission
: HOTH At Hoth Therapeutics, we strive to develop innovative, impactful, and ground - breaking treatments with a goal to improve Our patient quality of life . We are a catalyst in early - stage pharmaceutical research and development, elevating Mission promising drugs from the bench to pre - clinica
Slide 4: Key Investment Highlights
: HOTH Key Investment Highlights Clinical Programs Robust Pre - Clinical Development Programs Targeting Unmet Experienced Medical Needs to Management and Address Broad Market Advisory Board
Slide 5: Pipeline
: HOTH PROOF OF IND - PRODUCT DISEASE CONCEPT PRECLINICAL ENABLING PHASE 1 PHASE 2 PHASE 3 LAUNCH Mast-Cell Derived Cancers Pipeline : Oncology HT-KIT Skin Toxicity Associated Multiple Shots HT-001 with EGFR Inhibitors on Goal Neurology HT-ALZ Alzheimer’s Disease Dermatology BioLexa Atopic Dermatiti
Slide 6: Primary Development
: HOTH Primary Development HT - 001 Topical Gel HT - KIT Injection
Slide 7: HT-001: Market Growth and Value Proposition
: HOTH Market Growth: EGFR Inhibitor Skin Toxicity market predicted to grow from $52M in 2018 to $391M by end of 2030* HT - 001 : Value Proposition Mechanism of Action: HT - 001’s active ingredient is a n eurokinin 1 receptor agonist (NK1RA) that has been shown to have anti - inflammatory properties
Slide 8: Recent & Upcoming Milestones: HT-Topical Gel
: HOTH Recent & Upcoming Milestones : HT - 001 Topical Gel Q3 2024 Q1 2025 Q3 2025 Q1 2026 Positive Case Study Positive Initial Interim Submission to European Full Data Set for Open Results Open Label PK Cohort Medical Agency for Label PK Cohort Data Results Clinical Trial Expansion in EU
Slide 9: First in Human Clinical Trial
6-Week Treatment Period 2-Week Follow Up : HOTH Open-label treatment with HT-001 2% (n=12 patients) First in Randomized, Double Blind treatment with HT-001 0.5%, 1%, 2% API or placebo (n=140 patients) Human Clinical Trial : Preliminary data from CLEER - 001 Phase 2a Open - label cohort show Dose Ran
Slide 10: Case Study at GW Published Sept 2024
59 y/o F with history of metastatic breast cancer with bilateral : HOTH lung nodules presented with pruritic, burning red papules on the face, scalp, and upper back. Case Study* at Began paclitaxel, trastuzumab, and pertuzumab two weeks prior to onset. GW Published Sept 2024 : HT - 001 Baseline 1 Mo
Slide 11: HT-001 505(b)(2) Development Pathway
: HOTH HT - 001 505 (b)(2) PK Cohort Type C FDA EOP2 FDA Pre - NDA IND Development Submission Results Meeting Meeting Meeting Pathway 2023 2026 2027 2028 2029 2030 Phase 3 NDA Phase 2a Clinical Study Phase 2b Clinical Submission Clinical Study Study (US and EU) In - Process Chronic Toxicology Regist
Slide 12: Proactive Topical HT-001 Significantly Reduces EGFR Inhibitor Induced Cutaneous Toxicity
Erlotinib – Week 12 : HOTH Group Change Change Compared to Compared Proactive Erlotinib to Erlotinib Only Group: Only Group: Topical HT - Facial Skin Hair Loss at Lesions at 12 12 weeks 001 weeks Significantly Erlotinib + Topical HT - 001 Initiated Week 1 – Week 12 Reduces EGFR Preventati 58.5% 56.2
Slide 13: HT-KIT: Market Growth and Value Proposition
: HOTH Market Growth: Global systemic mastocytosis treatment revenue is $128M and projected to grow at 5.8% CAGR HT - KIT : through 2031* Value Proposition Mechanism of Action: HT - KIT is an antisense oligonucleotide that results in non - functional cKIT via mRNA frameshift.** Addresses Unmet Need:
Slide 14: Recent & Upcoming Milestones: HT-KIT Injection
: HOTH Recent & Upcoming Milestones : HT - KIT Injection Q4 2023 Q1 2024 Q1 2026 Q4 2026 Pre-IND Meeting with FDA IND-Enabling Animal Initiate Final Animal IND Submission Target and Strategy Confirmed Toxicology Studies Initiated Toxicology studies and Manufacture Clinical Batches
Slide 15: HT-KIT Orphan Drug Development Pathway
: HOTH HT - KIT Pivotal Clinical Orphan Drug Pre - IND Meeting IND Submission Studies (TBD) Development Pathway 2023 2024 2025 2026 2027 2028 IND - Enabling Clinical Readiness: Phase 1b Safety Toxicology Studies • GMP Drug and Preliminary Manufacture Efficacy Study in • Clinical Protocol patients wi
Slide 16: HT-KIT Inhibits Tumor Growth in Xenograft Model
: HOTH Systemic delivery of human HT - KIT inhibits tumor growth in a humanized xenograft mast cell neoplasia model HT - KIT Figures from Douglas B. Snider1, Greer K. Arthur1, Guido H. Falduto2, Ana Olivera2, Lauren C. Ehrhardt - Humbert1, Emmaline Smith 1, Cierra Smith1, Dean D. Metcalfe2 and Glenn
Slide 17: HT-KIT Reduces Liver Infiltration of Neoplastic Mast Cells
: HOTH HT - KIT Reduces Liver Infiltration of Neoplastic Mast Cells in a Humanized Xenograft Model of Mast Cell Neoplasia Figures from Douglas B. Snider1, Greer K. Arthur1, Guido H. Falduto2, Ana Olivera2, Lauren C. Ehrhardt - Humbert1, Emmaline Smith 1, Cierra Smith1, Dean D. Metcalfe2 and Glenn Cr
Slide 18: Preclinical Development
: HOTH Preclinical Development HT - ALZ Oral Film HT - VA
Slide 19: HT-ALZ: Market Growth and Value Proposition
: HOTH Market Growth: The Global Alzheimer’s Disease Treatment Market is expected to grow at a CAGR of around 12.8% from 2020 to 2027 and reach the market value of over $5.2B by HT - ALZ : 2027.* Value Proposition Mechanism of Action: HT - ALZ targets the Substance P/Neurokinin - 1 Receptor pathway*
Slide 20: Recent & Upcoming Milestones: HT-ALZ Oral Soluble Film
: HOTH Recent & Upcoming Milestones : HT - ALZ Oral Soluble Film Q2 2024 Q3 2024 Q3 2024 2025 HT-ALZ Formulation Work US Patent Office Awarded Preclinical Studies Pre-IND Meeting initiated HT-ALZ Patent completed at WashU Submission
Slide 21: HT-VA: Market Growth and Value Proposition
: HOTH HT - VA : Market Growth: The global obesity treatment market size was valued at USD 15.92 billion in 2024 and is projected to Value Proposition reach USD 60.53 billion by 2030, growing at a CAGR of 22.31% from 2025 to 2030.* Mechanism of Action: A GDNF family receptor alpha - 1 (GFR α- 1) ago
Slide 22: Recent & Upcoming Milestones: HT-VA
: HOTH Recent & Upcoming Milestones : HT - VA Q1 2025 Q2 2025 Q3 2025 Q1 2026 Obtained License Completed CRADA Initiate Preclinical Studies Initial Results from Agreement from Veteran’s Development and Executed under CRADA Preclinical Studies Affairs for HT-VA
Slide 23: Investment Highlights
• Addressing multi - billion - dollar unmet market opportunities across indications : HOTH Programs in Clinical Stage of • HT - 001 – no approved product/competitor currently on the market, Development clinical trial currently enrolling • HT - KIT – Pre - IND Meeting with FDA successful and IND - en
Slide 24: Thank You.
: HOTH Thank You. Contact Information Investor Relations: Hoth Therapeutics, Inc. investorrelations@hoththerapeutics.com : HOTH
Hoth Therapeutics — Investor Presentation (October 2025) on 6ix